PRESS RELEASE : APEIRON Biologics Announces Changes to Management and Supervisory Boards

DGAP-News: APEIRON Biologics AG / Key word(s): Personnel 
APEIRON Biologics Announces Changes to Management and Supervisory Boards 
2021-06-01 / 10:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
APEIRON Biologics Announces Changes to Management and Supervisory Boards 
  . Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and 
    Andreas Gerber, PhD, as Chief Operating Officer (COO) 
  . Prof. Josef Penninger moves from the Supervisory Board to the newly created Scientific Advisory Board, which he 
    will build up and lead as Chairman 
  . APEIRON to propose Ulrich Granzer PhD as new member of the Supervisory Board at the upcoming Annual General Meeting 
Vienna, Austria, 1 June 2021: APEIRON Biologics AG, a privately held biotechnology company developing novel 
immunotherapies for cancer and respiratory diseases, today announced changes to the Company's Management and 
Supervisory Boards. 
In order to meet the Company's growth requirements, the Supervisory Board has decided to expand the Management Board 
and strengthen the Company's Supervisory Board and Scientific Advisory Board. Romana Gugenberger, PhD, previously Head 
of Research & Development at APEIRON Biologics, will be entrusted with the new Management Board role of Chief Medical & 
Scientific Officer (CMSO) effective 1 June 2021. Andreas Gerber, PhD, previously Site Head & Executive Director 
Biologics and Vaccines Formulation at Merck Sharpe & Dohme, will be appointed Chief Operating Officer (COO) as of the 
same date. 
Prof. Josef Penninger, founder and long-standing member of the Supervisory Board of APEIRON Biologics AG, will move to 
the newly created Scientific Advisory Board, which he will build up and lead as Chairman. As a new member of the 
Supervisory Board, the Company proposes Ulrich Granzer, PhD, founder and managing director of the consulting firm 
Granzer Regulatory Consulting & Services, who will stand for election at the Annual General Meeting on 21 June 2021. 
Dr. Manfred Reichl, Chairman of the Supervisory Board of APEIRON Biologics, commented, "The APEIRON team around CEO 
Peter Llewellyn-Davies has achieved tremendous progress in the development of several innovative cancer therapeutics 
and a COVID-19 drug in recent years. With the expansion of the Board, the Company is now preparing for its next 
clinical and commercial growth steps. We welcome Romana Gugenberger in her new role; as Head of Research & Development 
at APEIRON, she has already impressively demonstrated her scientific expertise and leadership skills. We are also very 
pleased to bring Andreas Gerber on board, who will bring his many years of operational leadership experience in 
development and commercialization in international pharmaceutical companies." 
Prof. Josef Penninger, founder of APEIRON and Chairman of the new Scientific Advisory Board, says: "I am proud of the 
great achievements APEIRON has reached over the last months and years. To further strengthen the scientific acumen of 
the Company, an Advisory Board will be established that will be composed of high caliber global experts from different 
areas of biopharmaceutical research and development. As Chairman of the Scientific Advisory Board, I will work with the 
panel to provide our combined scientific expertise and development experience." 
Peter Llewellyn-Davies, CEO of APEIRON Biologics AG, explains: "I am delighted to welcome Romana Gugenberger and 
Andreas Gerber to the Management Board. The strengthening of the team and the addition of the new Scientific Advisory 
Board around Josef Penninger represents a logical further development step for APEIRON and an important reinforcement 
for our advanced and innovative projects. Likewise, the expertise of Ulrich Granzer will be of increasing importance to 
our progressing therapies, particularly in regulatory affairs. Together with the APEIRON team, I am very much looking 
forward to working together." 
As previously announced, Rainer Burian will step down from the APEIRON Supervisory Board at the end of his term of 
office on 21 June 2021. In his place, the Annual General Meeting had elected Edward Charles, Managing Director of the 
investment company Franklin Road, to the Supervisory Board in October 2020. 
Dr. Manfred Reichl: "The Supervisory Board and the Management Board would like to express their sincere thanks to Josef 
Penninger and Rainer Burian for their outstanding contribution to APEIRON Biologics over many years as members of the 
Supervisory Board. We highly appreciate that Prof. Penninger, with his world-leading expertise and networking in the 
field of the ACE2 enzyme and innovative cancer therapies, will continue to be on board in a key advisory role. We would 
also like to welcome Ulrich Granzer and Ed Charles with their proven experience to the Supervisory Board. We believe 
that the Management and Supervisory Boards, with their international focus and profound expertise, are now very well 
positioned to continue APEIRON's success." 
The Company's Annual General Meeting will be held as an online event on 21 June 2021. 
The new members of the Management Board and Supervisory Board: 
Romana Gugenberger, PhD, has headed the Research & Development department at APEIRON Biologics since 2020. She has been 
with the Company for 12 years, leading non-clinical and clinical projects, including in particular the autologous cell 
therapy APN401. Romana Gugenberger received her PhD in molecular biology from the University of Vienna and worked for 
several years at the Medical University of Vienna in the field of cardiovascular research and tumor biology. 
Andreas Gerber, PhD, has multiple years of experience in the pharmaceutical industry. Before joining APEIRON Biologics, 
he served as Site Head & Executive Director Biologics and Vaccines Formulation at Merck Sharpe & Dohme. Previously, he 
was responsible for the development of various active pharmaceutical ingredients and their production at Novartis 
Austria and managed a production site for biologics in Kundl, Austria. Andreas received his PhD from the University of 
Basel with a thesis on solid phase peptide synthesis and an Executive MBA from the University of St. Gallen. 
Ulrich Granzer, PhD, has been running a leading European regulatory affairs and clinical development consultancy in 
Munich since 2002. He has an excellent overview of current drug development programs as well as detailed insights into 
the requirements of key regulatory authorities. Previously, he was responsible for regulatory affairs worldwide at 
Bayer AG and BASF Pharma Knoll. Granzer began his career at Glaxo Wellcome. He received his PhD in Pharmaceutical 
Chemistry from the University of Tübingen, Germany. 
About APEIRON Biologics AG 
APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and 
development of treatments for respiratory diseases and novel cancer immunotherapies. 
APEIRON received EU marketing approval for APN311 (dinutuximab beta, Qarziba^(R)) in 2017 for the treatment of 
pediatric neuroblastoma patients and out-licensed global, exclusive rights for this product to EUSA Pharma Ltd. 
Apeiron is developing a promising drug for Covid-19: APN01 (rhsACE2, alunacedase alfa), a soluble recombinant version 
of the SARS-CoV-2 cell entry receptor ACE2. APN01 has three distinct potential clinical benefits for COVID-19 and has 
completed a double blind, placebo-controlled Phase 2 trial in Europe and Russia. Based on promising results, APN01 was 
selected for a publicly funded, large-scale study in COVID-19 funded by the U.S. government which is scheduled to start 
in Q2 2021. 
APN401's proprietary cellular therapy process brings in a paradigm change in cancer treatment to fight hematological 
and solid tumors. The clinical program is a first-in-class ambulatory autologous transient therapy to strengthen immune 
reactivity via an intracellular master checkpoint inhibitor, Cbl-b. 
APEIRON Biologics' projects and technologies are based on a strong patent portfolio and partnerships with leading 
pharmaceutical companies and academic institutions. 
Further information, visit www.apeiron-biologics.com and connect with us on Twitter and LinkedIn. 
For further information please contact: 
APEIRON Biologics AG 
Peter Llewellyn-Davies 
CEO 
Email: [e-mail] 
www.apeiron-biologics.com 
Media and Investor Relations 
MC Services AG 
Julia Hofmann, Andreas Jungfer 
T [phone] 
Email: [e-mail] 
 
FORWARD LOOKING STATEMENTS 
Information set forth in this press release contains forward-looking statements, which involve a number of risks and 
uncertainties. The forward-looking statements contained herein represent the judgement of APEIRON Biologics as of the 
date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a 
variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to 
differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or 
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our 
expectations or any change in events, conditions or circumstances on which any such statement is based. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-01 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 

(MORE TO FOLLOW) Dow Jones Newswires

June 01, 2021 04:00 ET (08:00 GMT)